Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study: Navigators Help Breast Cancer Patients Get Recommended Care

July 30, 2014
By Janet Colwell
Article

Patient navigators can play an important role in helping poor and underserved women overcome barriers to receiving recommended care for breast cancer, a recent study found.

Patient navigators can play an important role in helping poor and underserved women.

Patient navigators can play an important role in helping poor and underserved women overcome barriers to receiving recommended care for breast cancer, a recent study found.

Researchers performed a secondary analysis of women diagnosed with breast cancer who participated in the Patient Navigation Research Program (PNRP) to determine whether they received recommended anti-estrogen therapy, radiation, or chemotherapy. Compared to non-navigated patients, navigated patients were more likely to receive anti-estrogen therapy but no more likely than controls to receive radiation (data was insufficient to assess impact on chemotherapy). The findings were published online July 28 in the Journal of Clinical Oncology.

“These results suggest that patient navigation can be a promising solution/intervention,” the authors wrote, “particularly because the current literature suggests that minority women of low socioeconomic status are at risk of low adherence to anti-estrogen therapy.”

The study is based on data collected at 10 research centers between 2006-2011 on over 1,000 women with breast cancer participating in the PNRP, sponsored by the National Cancer Institute and the American Cancer Society.  Participants had a mean age of 56 years and were racially and ethnically diverse (38% black; 22% Hispanic; 36% white; and 4% other).

It is not clear why patient navigation was more effective in helping patients receive anti-estrogen therapy than radiation therapy, the authors said. However, they speculated that it may have been more difficult for navigators to deal with obstacles associated with receiving radiation treatment as opposed to obtaining prescriptions or educating patients to facilitate anti-estrogen therapy.

“Barriers addressed in radiation therapy may require a different set of actions compared with assistance in obtaining anti-estrogen therapy,” the authors wrote. “For example, assistance with transportation or managing work schedules could have played a more prominent role.”

More research is needed to confirm the study’s findings and address questions that it raises, such as how navigation improves receipt of recommended treatment and which populations and settings would most benefit from it, researchers said.

“Our lack of a consistent finding in favor of navigation for all three quality treatment metrics suggests that the benefits of navigation may depend on the type of barriers addressed (eg, financial, transportation) and personal interaction (education and/or understanding regarding illness, treatment, and so on),” the authors said. “Targeting resources to the right area (eg, timeliness, transportation, or logistical help) will identify which aspects of care are best suited for patient navigation to make a difference.”

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer

Andrea Eleazar, MHS
October 19th 2025
Article

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

Kristie L. Kahl
October 19th 2025
Article

Gedatolisib enhanced PFS in advanced breast cancer, showcasing significant benefits when combined with fulvestrant and palbociclib.


T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

T-DXd-Based Neoadjuvant Therapy Improves pCR in High-Risk, HER2+ Breast Cancer

Chris Ryan
October 18th 2025
Article

T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

Related Content
Advertisement

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer

Andrea Eleazar, MHS
October 19th 2025
Article

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer

Kristie L. Kahl
October 19th 2025
Article

Gedatolisib enhanced PFS in advanced breast cancer, showcasing significant benefits when combined with fulvestrant and palbociclib.


T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

T-DXd-Based Neoadjuvant Therapy Improves pCR in High-Risk, HER2+ Breast Cancer

Chris Ryan
October 18th 2025
Article

T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.